DEF 14A: Yield10 Bioscience Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance

Yield10 Bioscience is asking stockholders to approve a reverse stock split to increase its share price and maintain its Nasdaq listing.

Summary

• Yield10 Bioscience is holding a special meeting of stockholders on April 26, 2024, to vote on two proposals.
• The first proposal is to amend the company's certificate of incorporation to effect a reverse stock split of its common stock at a ratio between 1-for-5 and 1-for-25.
• The second proposal is to adjourn the special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the reverse stock split proposal.
• The Board of Directors recommends voting FOR both proposals.
• The company received a notification from Nasdaq on September 25, 2023, that its stock price had fallen below $1.00 per share for 30 consecutive business days, putting it in non-compliance with Nasdaq's minimum bid price requirement.
• As of April 3, 2024, the closing price of Yield10's common stock was $0.31 per share.
• The reverse stock split, if approved, would reduce the number of outstanding shares and potentially increase the stock price to regain compliance with Nasdaq listing requirements.
• As of the record date, April 1, 2024, there were 15,401,706 shares of common stock outstanding.
• If a 1-for-5 reverse stock split is effected, there will be approximately 3,080,341 shares outstanding.
• If a 1-for-25 reverse stock split is effected, there will be approximately 616,068 shares outstanding.
• The Board of Directors will determine whether to effect the reverse stock split no later than July 31, 2024.

Sentiment

Score: 5

Explanation: The document is neutral in tone, presenting the facts regarding the need for a reverse stock split. While the company expresses optimism about maintaining its Nasdaq listing, there are inherent risks and uncertainties associated with the proposal.

Positives

• Maintaining the Nasdaq listing may provide a broader market for the company's common stock.
• A higher stock price may facilitate future financings and increase investor interest.
• The reverse stock split would increase the number of shares available for issuance in future financings and other purposes.
• The company believes that a higher stock price may help generate investor interest in us, including interest among institutional investors.

Negatives

• There is no guarantee that the reverse stock split will result in a sustained increase in the per share price of the common stock.
• The reverse stock split could lead to a loss of value if the share price does not rise proportionately.
• If the market price of the common stock declines after the reverse stock split, the percentage decline may be greater than it would have been without the split.
• The liquidity of the common stock could be adversely affected by the reduced number of shares outstanding after the reverse stock split.

Risks

• The company may not be able to maintain compliance with Nasdaq listing requirements even after implementing the reverse stock split.
• Delisting from Nasdaq could make it more difficult to sell the company's common stock and raise additional capital.
• The reverse stock split may not attract brokers and investors who do not trade in lower-priced stocks.
• The market price of the company's common stock will also be based on its performance and other factors, some of which are unrelated to the number of shares outstanding.

Future Outlook

The company intends to conduct a reverse stock split to cure the deficiency in the minimum bid price requirement and maintain its Nasdaq listing, but there is no guarantee that this will be successful.

Management Comments

• The Board of Directors believes that maintaining our listing on Nasdaq may provide a broader market for our common stock and facilitate the use of our common stock in financing and other transactions.
• The Board of Directors believes that effecting the reverse stock split may be an effective means of regaining compliance with the bid price requirement for the continued listing of our common stock on Nasdaq.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. Other companies in similar situations may consider this approach to regain compliance.

Comparison to Industry Standards

• Many biotechnology companies with promising technologies but limited revenue have faced similar challenges with maintaining exchange listings.
• Comparable companies that have implemented reverse stock splits to maintain compliance include [hypothetical company A] and [hypothetical company B].
• The success of a reverse stock split in increasing stock price and maintaining compliance varies depending on the company's underlying fundamentals and market conditions.

Stakeholder Impact

• Shareholders will be affected by the reverse stock split, potentially seeing a change in the number of shares they own and the per-share price.
• Employees may be affected if the company's Nasdaq listing is not maintained, potentially impacting the company's ability to raise capital and grow.
• The company's ability to attract investors and partners could be affected by its Nasdaq listing status.

Next Steps

• Stockholders will vote on the reverse stock split proposal at the Special Meeting on April 26, 2024.
• If approved, the Board of Directors will determine the ratio of the reverse stock split and file a certificate of amendment with the Secretary of State of Delaware.
• The company will notify stockholders of the effective date of the split and provide instructions for exchanging stock certificates.

Key Dates

Keywords

reverse stock split, Nasdaq, compliance, stock price, Yield10 Bioscience, proxy statement, stockholders, common stock, listing, shares